Exelixis announced data from its Phase 2 study of cabozantinib (XL184) for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). This study is an ongoing, adaptive, randomized, discontinuation trial. The data support the findings that cabozantinib reduces or stabilizes metastatic bone lesions in nearly all patients evaluable by bone scan, reduces bone pain and narcotic analgesic medication, and results in an increase in hemoglobin in patients with anemia.
Cabozantinib is an inhibitor of tumor growth, metastasis and angiogenesis, and simultaneously targets MET and VEGFR2–key kinases involved in the development and progression of many cancers, including CRPC.
For more information call (650) 837-7000 or visit www.exelixis.com.